1. KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells. Issue 7 (14th April 2015) Authors: Leiser, Dominic; Medová, Michaela; Mikami, Kei; Nisa, Lluís; Stroka, Deborah; Blaukat, Andree; Bladt, Friedhelm; Aebersold, Daniel M.; Zimmer, Yitzhak Journal: Molecular oncology Issue: Volume 9:Issue 7(2015:Aug.) Page Start: 1434 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗